{"disease":{"id":"multiple-myeloma-mm-lymphoma-large-b-cell-diffuse-dlbcl-lymphoma","name":"multiple myeloma mm lymphoma large b cell diffuse dlbcl lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07309497","title":"Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)","phase":"","overall_status":"RECRUITING","enrollment_count":208,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT07305337","title":"Randomised Controlled Trial of Artificial Intelligence-assisted Health Education","phase":"NA","overall_status":"RECRUITING","enrollment_count":196,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT07270263","title":"Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Medical University of Gdansk","has_results":false},{"nct_id":"NCT07410494","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT02992483","title":"Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}